Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Intravenous Epoetin Alfa to Maintenance Treatment With Intravenous RO0503821 in Hemodialysis Patients With Chronic Renal Anemia.
Brief Summary: This study will determine the appropriate dose and frequency of administration of iv Mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.


Options:
A: Arm Label: Cohort 1 (RO0503821 [0.25/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 2 (RO0503821 [0.25/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 3 (RO0503821 [0.4/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 4 (RO0503821 [0.4/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 5 (RO0503821 [0.6/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 6 (RO0503821 [0.6/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): Cohort 1 (RO0503821 [0.25/150 1x/week]), Cohort 2 (RO0503821 [0.25/150 1x/2week]), Cohort 3 (RO0503821 [0.4/150 1x/week]), Cohort 4 (RO0503821 [0.4/150 1x/2week]), Cohort 5 (RO0503821 [0.6/150 1x/week]), Cohort 6 (RO0503821 [0.6/150 1x/2week])
B: Arm Label: HD treated with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Arm Label: post-dilution oHDF with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Arm Label: pre-dilution oHDF with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: HD treated with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: post-dilution oHDF with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: pre-dilution oHDF with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Intervention Type: DEVICE; Name: Citrate dialysate (CiDi); Assigned to Arm(s): HD treated with citrate dialysate, post-dilution oHDF with citrate dialysate, pre-dilution oHDF with citrate dialysate | Intervention Type: DEVICE; Name: Standard dialysate (StDi); Assigned to Arm(s): HD treated with standard dialysate, post-dilution oHDF with standard dialysate, pre-dilution oHDF with standard dialysate
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Lisinopril | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A

Answer: A